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Background: Despite the public health significance of annual influenza outbreaks, the literature comparing the
epidemiology of influenza A and B infections is limited and dated and may not reflect recent trends. In Canada, the
relative contribution of influenza A and B to the burden of morbidity is not well understood. We examined rates of
laboratory-confirmed cases of influenza A and B (LCI-A and LCI-B) in the Canadian province of Manitoba between
1993 and 2008 and compared cases of the two types in terms of socio-demographic and clinical characteristics.
Methods: Laboratory-confirmed cases of influenza A and B in Manitoba between 1993 and 2008 were identified
from the Cadham Provincial Laboratory (CPL) Database and linked to de-identified provincial administrative health
records. Crude and age-adjusted incidence rates of LCI-A and LCI-B were calculated. Demographic characteristics,
health status, health service use, and vaccination history were compared by influenza type.
Results: Over the study period, 1,404 of LCI-A and 445 cases of LCI-B were diagnosed, corresponding to an annual
age-standardized rate of 7.2 (95% CI: 6.5-7.9) for LCI-A and 2.2 (CI: 1.5 – 3.0) per 100,000 person-years for LCI-B.
Annual rates fluctuated widely but there was less variation in the LCI-B rates. For LCI-A, but not LCI-B, incidence was
inversely related to household income. Older age, urban residence and past hospitalization were associated with
increased detection of LCI-A whereas receipt of the influenza vaccine was associated with decreased LCI-A detection.
Once socio-demographic variables were controlled, having a pre-existing chronic disease or immune suppression was
not related to influenza type.
Conclusion: Influenza A and B affected different segments of the population. Older age was associated with increased
LCI-A detection, but not with pre-existing chronic diseases. This information may be useful to public health professionals
in planning and evaluating new and existing seasonal influenza vaccines.
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Annual epidemics of influenza are an important public
health problem globally and in Canada [1]. Each year,
10-25% of the Canadian population become infected
with influenza [2]. Most of these infections are typically
asymptomatic or associated with a mild self-limiting illness
[3]. However, influenza can cause severe illness leading to
hospitalization and death, especially among the very young,* Correspondence: Salah.mahmud@gmail.com
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unless otherwise stated.the elderly and those with underlying chronic conditions
[3,4]. It has been estimated that on average about 4,000
influenza-related deaths occur in Canada each year [5].
Influenza is caused by small negative-sense single
stranded RNA viruses that belong to one of three genera
(Influenza virus A, B and C) of the family Orthomyxo-
viridae [6]. Influenza C, which is typically associated
with mild illness in children [3], is of little clinical or
epidemiologic significance. Although influenza A and B
types are indistinguishable morphologically and share
similar clinical presentations and epidemiological features,
they differ in several important ways. Unlike influenza A,
which infects many bird and mammalian species, thehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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seals [7]). Because of the lack of animal reservoir, influ-
enza B has a lower rate of antigenic drift and does not
cause pandemics, although it could still cause signifi-
cant epidemics [8].
Although it is widely accepted that influenza B viruses
are more likely to infect children and to cause milder
illness than are influenza A viruses [9], the literature
comparing the epidemiology of influenza A and B infec-
tions is limited and dated and may not reflect recent
trends [10]. In Canada, the relative contribution of influ-
enza A and B to the burden of morbidity is not well
understood.
The objectives of this population-based study were to
examine rates of laboratory-confirmed cases of influenza
A and B in the Canadian province of Manitoba between
1993 and 2008 and to compare cases of these two influ-




This study was conducted using de-identified records
obtained by linking the electronic database of Cadham
Provincial Laboratory (CPL) with other Manitoba Health
(MH) administrative databases, housed at the Manitoba
Centre for Health Policy. The study was approved by the
Research Ethics Board of the University of Manitoba and
the Health Information Privacy Committee of MH.
MH is the publicly funded government department
providing comprehensive health insurance, including
coverage for laboratory, hospital and outpatient phys-
ician services, to the province’s 1.2 million residents.
Coverage is universal (there is no eligibility distinction
based on age or income) and participation rates are very
high (>99%) [11]. Only RCMP and military personnel,
whose health benefits are fully covered by the federal
government, are not included [12]. For administrative
purposes, MH maintains several centralized electronic
databases that can be linked using a unique health ser-
vices number (PHIN). The completeness and accuracy
of the MH databases are well established [13,14], and
these databases have been used extensively, by our team
and others, in studies of influenza surveillance and vac-
cine evaluation [15-17].
Identification of influenza A and B cases
We used the database of CPL, the province’s only
virology laboratory, to identify all individuals diagnosed
in Manitoba with laboratory-confirmed influenza (LCI)
A or B between 1993 and 2008 (the study period). This
database has stored results of all influenza testing per-
formed in the province since the early 1980s [18]. Over
the study period, influenza testing was mostly performedusing viral cultures or more recently Poymerase Chain
Reaction (PCR) and very occasionally using other tests
including antigen detection, fluorescence microscopy
and egg inoculation.
For the purpose of this analysis, multiple positive tests
for the same person were counted as a single incident
infection if they were performed within 13 days of each
other. Positive tests performed 14 or more days apart
were considered as separate cases. Since the date of
symptom onset was not available in the laboratory data,
the specimen collection date was used as the index date
(epidate) in this study. In instances where the specimen
date was missing, the date the specimen was received or
tested was used instead.
To be included in the analysis, individuals with LCI
had to be residents of Manitoba and have MH coverage
when they were tested. Eligibility was ascertained by
linking the CPL database, using the scrambled PHIN,
with MH Population Registry, a continuously updated
registry that stores basic demographic information on all
insured Manitobans, and gathers information on dates
and reasons for the initiation and termination of health
care coverage (e.g., birth, migration in or out of province
and death).
Measurement of covariates
Sex, age, and region of residence at the index date were
obtained from the MH Population Registry. Household
income quintiles, measured at the level of the census
dissemination area, were determined using the 2006
Canadian census data. Information on propensity to seek
health care and on relevant pre-existing health condi-
tions was obtained from hospital and physician claims
databases. Since 1971, the Hospital Abstracts database
recorded virtually all services provided by hospitals in
the province, including admissions and day surgeries.
[12] The data collected comprise demographic as well as
diagnosis and treatment information including primary
diagnosis and service or procedure codes, coded using
the International Classification of Diseases, Ninth Revi-
sion, Clinical Modification (ICD-9-CM) before April,
2004, and the ICD-10-CA [19] (Canadian adaptation of
the ICD-10 [20]) and the Canadian Classification of
Health Interventions (CCI) [21] afterwards. The Medical
Services database, also in operation since 1971, collects
similar information, based on physician fee-for-service
or shadow billing, on services provided by physicians in
offices, hospitals and outpatient departments across the
province [12]. Each billing record includes a tariff code
and a 3-digit ICD-9 code which identifies the principal
diagnosis or main reason for the visit.
We used previously validated algorithms, based on the
frequency of certain International Classification of Dis-
eases’ codes, to identify chronic diseases such as asthma,
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conditions) [22,23]. Immunosuppression was defined as
having a diagnosis of HIV/AIDS, other immune defi-
ciency disorders or cancer (other than non-melanoma
skin cancer), or receiving prescriptions for immunosup-
pressive drugs [24]. Information on the use of immune
suppressants was obtained from DPIN, the comprehen-
sive database of all out-of-hospital prescriptions dis-
pensed in Manitoba since 1995. In addition, Charlson
comorbidity scores were calculated using an algorithm
validated for electronic databases [25].
Information on the receipt of all vaccines, including
the seasonal influenza vaccines (Trivalent Influenza Vaccines
(TIV)) and pneumococcal vaccines was obtained from
the Manitoba Immunization Monitoring System (MIMS),
the population-based province-wide registry recording all
immunizations administered to Manitoba residents since
1988 [26]. Information, including vaccine type and date of
immunization, is captured for each immunization event
either through direct data entry for vaccines administered
by public health staff or using physician claims data for
vaccines administered by physicians [27].
Statistical analysis
Annual age-standardized incidence rates were calculated
separately for influenza A and B cases using population
estimates obtained from the MH Population Registry as
the denominator and the 2006 Canadian population as
the standard population. Age-standardized rates were
also calculated for subsets of the population defined by
gender, area of residence, and income quintiles.
We described and compared the demographic and
clinical profiles of the influenza A and B cases, and used
unconditional logistic regression models to estimate the
odds ratio (OR), and 95% confidence intervals (95%CI),
for the association between the detection of LCI-A and
B infections and several socio-demographic and clinical
factors. Selection of variables for inclusion in the model
was guided by what is known from the literature and by
the extent that the inclusion of the variable improved
model fitness assessed using a likelihood ratio test.
Results
Over the study period, a total of 1849 LCI cases met
the eligibility criteria: 1404 (75.9%) were influenza A
whereas the other 445 were influenza B corresponding
to an age-standardized rate of 7.2 cases per 100,000
person-years (95% CI 6.5-7.9) for LCI-A and 2.2 per
100,000 (95% CI 1.5-3.0) for LCI-B (Table 1). LCI-A age-
specific rates were generally higher than the LCI-B rates
especially among infants and those 75 or older. For both
LCI-A and B, the age-specific rate was highest in infants,
and tended to decrease with age and then increase again
among those 75 or older.Annual rates fluctuated widely but there was less fluc-
tuation in the annual rates for LCI-B compared to the
typically much higher LCI-A rates (Figure 1). The annual
age-standardized rates of LCI-A ranged from 0.7 in 2004
to 21.0 per 100,000 person-years in 1999. Meanwhile,
the annual age-standardized rates for LCI-B ranged from
<0.5 in 1998, 2002, and 2007 to 7.8 per 100,000 person-
years in 2001.
LCI-B cases were younger with a median (range) age
of 13 (3–43) years compared to 42 (2–83) years for LCI-A.
For both LCI-A and B, the age-standardized rates did not
vary much by gender or area of residence. For LCI-A, but
not LCI-B, there was an income gradient, with age-
standardized rates decreasing from 8.7 (7.0 - 10.3) among
those residing in the poorest areas to 4.4 (2.6 - 6.1) per
100,000 person-years among those residing the wealthiest
areas. For both LCI-A and B, the highest rates were in the
unknown income quintile category, which includes indi-
viduals residing in personal care homes and similar long-
term care facilities.
The clinical characteristics of the laboratory-confirmed
influenza A and B cases are presented in Table 2. Com-
pared to LCI-B cases, a larger proportion of LCI-A cases
had pre-existing chronic diseases including asthma,
cardiovascular diseases, chronic obstructive pulmonary
disease and diabetes. They were also more likely to have
been hospitalized or seen a physician during the previ-
ous 5 years. While there was no significant difference
between the two groups in receiving the TIV, a larger
proportion of LCI-A cases were eligible to receive the
TIV but did not receive it. Lastly, 36.2% of LCI-A cases
received a pneumococcal vaccine compared to 25.2% of
LCI-B cases.
Table 3 presents the results from unadjusted models
of several demographic and clinical characteristics as
well as adjusted models that included terms for age
group, gender, region of residence and income quintiles.
Compared to infants, children between the ages of 2 and
9 years were less likely to test positive for influenza A
than influenza B (adjusted OR = 0.5 [95% CI 0.3-0.9] for
the 2- to 4-years-olds and OR = 0.4 [95% CI 0.3-0.7] for
the 5- to 9-years-olds). On the other hand, adults aged
65 or older were more likely to test positive for influenza
A, with an OR of 3.1 (95% CI 1.3-7.3) for 65- to 74-
years-olds and 2.4 (95% CI 1.5-3.7) for those 75 or older.
Residents in urban areas were 30% more likely to test
positive for influenza A than to influenza B. Individuals
who were hospitalized at least once in the last five years
were significantly more likely to test positive for influ-
enza A than B (OR = 1.7, 95% CI 1.3-2.3). Individuals
that received the seasonal influenza vaccine were signifi-
cantly less likely to test positive for influenza A than B
(OR = 0.6, 95% CI 0.4-0.9). Once socio-demographic
variables were controlled, having a pre-existing chronic
Table 1 Crude and age-standardized rates (per 100,000 person-years) of laboratory-confirmed influenza A and B cases
by certain socio-demographic characteristics (1993–2008)
Total
person-years






Rate 95% CI Rate 95% CI Rate 95% CI Rate 95% CI
Overall 18,559,978 1,404 7.6 7.2 - 8.0 7.2 6.5 - 7.9 445 2.4 2.2 - 2.6 2.2 1.5 - 3.0
Age group (years)
<=1 478,951 323 67.4 60.5-75.2 94 19.6 16.0-24.0
2 to 4 741,193 68 9.2 7.2-11.6 32 4.3 3.1-6.1
5 to 9 1,292,298 58 4.5 3.5-5.8 46 3.6 2.7-4.8
10 to 14 1,333,125 62 4.7 3.6-6.0 64 4.8 3.8-6.1
15 to 24 2,581,745 68 2.6 2.1-3.3 41 1.6 1.2-2.2
25 to 44 5,379,985 142 2.6 2.2-3.1 57 1.1 0.8-1.4
45 to 64 4,227,965 115 2.7 2.3-3.3 31 0.7 0.5-1.0
65 to 74 1,290,068 66 5.1 4.0-6.5 7 0.5 0.3-1.1
75+ 1,234,648 502 40.7 37.3-44.4 73 5.9 4.7-7.4
Sex
Female 9,412,486 758 8.1 7.5 - 8.6 7.4 6.3 - 8.4 245 2.6 2.3 - 3.0 2.4 1.4 - 3.5
Male 9,147,492 646 7.1 6.5 - 7.6 6.8 5.8 - 7.9 200 2.2 1.9 - 2.5 1.9 0.9 - 3.0
Locality of residence
Rural 7,268,040 604 8.3 7.7 - 9.0 7.7 6.5 - 8.9 240 3.3 2.9 - 3.7 2.9 1.7 - 4.1
Urban 11,291,938 800 7.1 6.6 - 7.6 6.9 5.9 - 7.8 205 1.8 1.6 - 2.1 1.7 0.8 - 2.7
Area of residence
North 1,138,287 126 11.1 9.3 - 13.2 8.4 5.1 - 11.6 42 3.7 2.7 - 5.0 2.3 0.3 - 7.1
South 17,421,691 1,278 7.3 6.9 - 7.7 7.0 6.2 - 7.8 403 2.3 2.1 - 2.6 2.2 1.4 - 2.9
Income quintiles
Q1 (lowest) 3,704,516 385 10.4 9.4 - 11.5 8.7 7.0 - 10.3 108 2.9 2.4 - 3.5 2.3 0.6 - 4.0
Q2 3,838,620 249 6.5 5.7 - 7.3 5.9 4.3 - 7.5 74 1.9 1.5 - 2.4 1.8 0.7 - 4.7
Q3 3,722,216 225 6.0 5.3 - 6.9 5.7 4.0 - 7.3 108 2.9 2.4 - 3.5 2.8 1.1 - 4.4
Q4 3,707,649 160 4.3 3.7 - 5.0 4.3 2.7 - 6.0 60 1.6 1.3 - 2.1 1.5 0.6 - 5.0
Q5 (highest) 3,315,922 135 4.1 3.4 - 4.8 4.4 2.6 - 6.1 48 1.4 1.1 - 1.9 1.3 0.4 - 5.7
Unknown 271,055 250 92.2 81.5 - 104.4 59.7 53.1 - 66.4 47 17.3 13.0 - 23.1 13.9 0.4 - 6.1
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chronic diseases were not related to influenza type
(Table 3).
Discussion
Interest in understanding the comparative epidemi-
ology and disease burden associated with influenza A
and B infections has been growing, partially because of
concerns about the effectiveness of existing TIVs in
preventing influenza B infections as evidenced by re-
cent publications from several jurisdictions showing
suboptimal effectiveness against influenza B infections
in some seasons [28-30]. In addition, the licensing and
introduction of several quadrivalent vaccines (QIVs),
targeting both influenza B lineages (Victoria andYamagata), has sparked debate about the incremental
utility and cost-effectiveness of using these vaccines in-
stead of conventional TIVs which only targets one or
the other lineage [31].
We used pre-collected population-based laboratory
and administrative data to examine recent trends in the
incidence of LCI-A to compare LCI-A and B cases in
terms of socio-demographic and clinical profiles. Study-
ing differences between influenza A and B infections at
the population level poses significant challenges which
may explain the relatively scant literature in this area.
Most influenza cases are not clinically detected either
because the infected persons are asymptomatic or
because they decide not to seek care. Also, most cases
can be managed conservatively, so a definitive laboratory
Table 2 Clinical characteristics of laboratory-confirmed influenza A and B cases (1993–2008)
Influenza A (n = 1,404) Influenza B (n = 445)
N % N % P-value†
Asthma 141 10.0 51 11.5 0.393
Any cardiovascular disease 585 41.7 110 24.7 <.001
Chronic obstructive pulmonary disease 242 17.2 45 10.1 <.001
Diabetes 133 9.5 20 4.5 <.001
Immunosuppressed 252 17.9 61 13.7 0.038
Any chronic disease* 625 44.5 145 32.6 <.001
Mean Charlson index (SD) 1 1.3 0 0.9 <.001
Any hospital admissions in last 5 years 1,046 74.5 252 56.6 <.001
Median hospital admission in last 5 years (IQR) 2 0 - 3 1 0 - 2 <.001
Had ≥37 physician visits in last 5 years 703 50.1 154 34.6 <.001
Median physician visit in last 5 years (IQR) 37 0 - 73 0 0 - 47 <.001
Received the seasonal influenza vaccine 242 17.2 64 14.4 0.158
Timing of receipt of the seasonal influenza vaccine 0.100
1-13 days before index date 10 0.7 0 0.0
≥14 days before the index date 232 16.5 64 14.4
Recommended receipt of the seasonal influenza vaccine <.001
Not recommended 305 21.7 187 42.0
Recommended and received 218 15.5 54 12.1
Recommended but not received 881 62.7 204 45.8
Received a pneumococcal vaccine 508 36.2 112 25.2 <.001
†P-values from a Chi-squared test.
*Defined as diagnosis with one of the following diseases: diabetes, chronic obstructive pulmonary disease, asthma, ischemic heart disease, chronic renal failure, or
cancer (excluding non-melanoma skin cancer).
Figure 1 Annual age-standardized rates by laboratory-confirmed influenza type, Manitoba 1993–2008.
Hinds et al. BMC Public Health  (2015) 15:35 Page 5 of 8
Table 3 Effect of demographic and clinical characteristics
on laboratory-confirmed influenza type
Variables Crude Adjusted*
OR 95% CI OR 95% CI
Age group (years)
<=1 Reference group
2 to 4 0.6 0.4 - 1.0 0.6 0.4 - 1.0
5 to 9 0.4 0.2 - 0.6 0.5 0.3 - 0.9
10 to 14 0.3 0.2 - 0.4 0.4 0.3 - 0.7
15 to 24 0.5 0.3 - 0.8 0.8 0.5 - 1.3
25 to 44 0.7 0.5 - 1.1 1.0 0.6 - 1.6
45 to 64 1.1 0.7 - 1.7 1.5 0.9 - 2.5
65 to 74 2.7 1.2 - 6.2 3.1 1.3 - 7.3
75+ 2.0 1.4 - 2.8 2.4 1.5 - 3.7
Female 1.0 0.8 - 1.2 0.8 0.7 - 1.0
Resides in an urban area 1.6 1.3 - 1.9 1.3 1.1 - 1.7
Income quintiles
Q1 (lowest) Reference group
Q2 0.9 0.7 - 1.3 1.0 0.7 - 1.5
Q3 0.6 0.4 - 0.8 0.6 0.5 - 0.9
Q4 0.7 0.5 - 1.1 0.9 0.6 - 1.4
Q5 (highest) 0.8 0.5 - 1.2 1.0 0.6 - 1.5
Unknown 1.5 1.0 - 2.2 1.0 0.6 - 1.5
Asthma 0.9 0.6 - 1.2 0.9 0.6 - 1.3
Any cardiovascular disease 2.2 1.7 - 2.8 0.8 0.5 - 1.1
Chronic obstructive pulmonary disease 1.9 1.3 - 2.6 1.3 0.9 - 1.9
Diabetes 2.2 1.4 - 3.6 1.2 0.7 - 2.0
Immunosuppressed 1.4 1.0 - 1.9 0.8 0.6 - 1.2
Any chronic disease 1.7 1.3 - 2.1 1.0 0.7 - 1.3
Charlson index 1.3 1.1 - 1.4 1.1 1.0 - 1.2
Any hospital admissions in last 5 years 2.2 1.8 - 2.8 1.7 1.3 - 2.3
Had ≥37 physician visits in last 5 years 1.9 1.5 - 2.4 1.0 0.8 - 1.4
Received the seasonal influenza vaccine 1.2 0.9 - 1.7 0.6 0.4 - 0.9
Received a pneumococcal vaccine 1.7 1.3 - 2.1 0.9 0.7 - 1.2
*Final adjusted models included each variable in conjunction with the
following covariates: age, sex, locality of residence and income (see text).
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differences between influenza types requires a definitive
laboratory diagnosis.
Confirmed cases likely represent a small minority of
all those who were infected [32,33]. Therefore, our study
likely underestimates the incidence of disease in the
population. Also, the number of detected cases largely
reflects the proportion of symptomatic patients who pre-
sented for medical care and were tested for the infection,
and is, therefore, likely to be influenced by regional dif-
ferences in access to medical care, physicians’ practices,
laboratory testing guidelines and other factors. Theextent to which these factors may bias comparisons of the
demographic and clinical characteristics of laboratory-
confirmed cases between the two types is not clear. Our
results likely reflect the reality of clinical cases in Manitoba
accurately, but may not be generalizable to other juris-
dictions with drastically different healthcare systems
and clinical guidelines.
We found that overall influenza A was more com-
monly detected. This is consistent with results from
national surveillance systems [34,35] and observational
studies from both temperate and tropical countries. In
the Netherlands, between 1992/93 and 2006/07, influ-
enza A was more prevalent than influenza B among
sentinel patients with influenza-like illness, although
there were a few seasons where influenza B was the
dominant type [36]. In a meta-analysis of studies con-
ducted in Latin America and the Caribbean, the pooled
percentage of total respiratory specimens positive for in-
fluenza ranged from 4.7% and 15.4% per year between
1999 and 2008 [37]. In general, influenza A positive
samples were more common than influenza B positive
samples; although there were a few years in a few coun-
tries where there was a higher percentage of influenza B
positive samples than influenza A positive samples [37].
In our study, after controlling various covariates, only
age, urban residence, previous hospitalization, and re-
ceipt of the TIV were significantly associated with influ-
enza type. Children 2 to 9 were less likely to test positive
for influenza A compared to infants and adults 65 years
and older. This could partially be a reflection of in-
creased severity of illnesses in these age groups and
therefore increased chance of detection. However, our
results are consistent with widely held belief that influ-
enza B is more likely to affect older children and young
adults [9], which may be explained by observations from
serologic studies that unvaccinated children accumulated
natural immunity to influenza B more slowly than to in-
fluenza A [31]. In addition, there is evidence that among
children, the TIV might be less effective in inducing
protection against opposite-lineage influenza B strains,
resulting in overall lower effectiveness against influenza
B in that age group [38]. We also found that individuals
who received the inactivated TIV (exclusively used in
Manitoba during the study period) were significantly less
likely to test positive for influenza A than B, which again
is consistent with the above explanation and with the
literature [39].
We saw evidence of an income gradient for influenza
A, such that age-adjusted rates were progressively lower
with higher average household income. This may reflect
increased susceptibility to infection, higher chance of
developing complications (leading to higher chance of
detection) or generally increased propensity to seek
healthcare among lower-income individuals. Although
Hinds et al. BMC Public Health  (2015) 15:35 Page 7 of 8the publically funded Canadian healthcare systems
improves access to healthcare services among lower-
income individuals, there is no reason to believe that
they will be more successful in negotiating obtaining
medically unnecessary influenza tests than socially
advantaged individuals.
Increased susceptibility is plausible. In fact, a very simi-
lar income gradient was observed in Manitoba for other
infectious diseases, including respiratory infections such
as tuberculosis and invasive pneumococcal disease, where
laboratory testing is less discretionary [40]. Also, during
the first wave of the 2009 pandemic, cumulative incidence
of H1N1 infection, as measured in seroprevalence studies,
was much higher in marginalized and socio-economically
disadvantaged populations [41,42]. In addition, lower-
income individuals in Manitoba, with higher levels of pre-
disposing conditions, were more likely to develop severe
illness requiring hospitalization [43,44], which is likely the
case with seasonal influenza too. There is a dearth of stud-
ies explicitly reporting on this association. Measures of
socioeconomic status were associated with the incidence
of influenza-like illness in one study, although, like in our
study, limited statistical power did not permit drawing
firm conclusions [45]. It is worth mentioning that institu-
tionalized people, who had the highest rates of LCI-A,
were not included in the income gradient analysis.
The strengths of our study include its population-based
design and relatively large sample size. Because of the
availability of accurate automated databases [46], this
study was less susceptible to measurement errors, for in-
stance in determining vaccination status. The complete-
ness and accuracy of the MH database are well established
[13]. However, it is possible that some variables were not
accurately measured. Misclassification of influenza type is
less likely because of the use of generally accurate diagnos-
tic tests [47]. But, we did not have information on viral
subtypes because subtyping was not performed routinely
on all isolates. We also did not have information on life-
style and environmental factors, so it was not possible to
assess the impact of these factors.
Conclusions
We found that in Manitoba influenza A was more com-
monly detected than influenza B during the study period.
Older age, urban residence and past hospitalization were
associated with increased detection of LCI-A whereas
receipt of the influenza vaccine was associated with
decreased LCI-A detection. Pre-existing health conditions
were not significantly associated with influenza type. This
information may be useful to public health professionals
in planning and evaluating new and existing seasonal
influenza vaccines. There was also evidence of an income
gradient for influenza A, which requires further explor-
ation in future research.Abbreviations
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